Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wm Kevin Kelly

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Current Treatment Options in Oncology|May 26, 2017
PARP Inhibitors in Prostate CancerPraveen Ramakrishnan Geethakumari, Matthew J Schiewer, Karen E Knudsen, et al.
The Journal of Urology|June 7, 2006
Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studiesSusan Halabi, Nicholas J Vogelzang, San-San Ou, et al.
Novartis Foundation Symposium|June 3, 2004
Histone deacetylase inhibitors: development as cancer therapyPaul A Marks, Victoria M Richon, Wm Kevin Kelly, et al.
Journal of Geriatric Oncology|May 4, 2024
The rates of septicemia in older adults with prostate cancer treated with abiraterone or enzalutamide: A population-based studyNikita Nikita, Krupa Gandhi, Scott W Keith, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|January 15, 2010
Prostate cancer, comorbidity, and participation in randomized controlled trials of therapyHerta H Chao, Tina Mayer, John Concato, et al.
Cancer Biology & Therapy|May 27, 2024
T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancerJulia Palecki, Amman Bhasin, Andrew Bernstein, et al.
Urologic Oncology|June 21, 2021
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?Jean Hoffman-Censits, Kara Lombardo, David McConkey, et al.
Cancers|September 13, 2025
The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical TrialsAmy L Shaver, Nikita Nikita, Swapnil Sharma, et al.
The Canadian Journal of Urology|October 25, 2011
Screening for prostate cancer: the current evidence and guidelines controversyLeonard G Gomella, Xiaolong S Liu, Edouard J Trabulsi, et al.
Contemporary Clinical Trials|December 25, 2022
Predictors of consenting to participate in a clinical trial among urban cancer patientsRussell K McIntire, Scott W Keith, Thomas Nowlan, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Current Treatment Options in Oncology|May 26, 2017
PARP Inhibitors in Prostate CancerPraveen Ramakrishnan Geethakumari, Matthew J Schiewer, Karen E Knudsen, et al.
The Journal of Urology|June 7, 2006
Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studiesSusan Halabi, Nicholas J Vogelzang, San-San Ou, et al.
Novartis Foundation Symposium|June 3, 2004
Histone deacetylase inhibitors: development as cancer therapyPaul A Marks, Victoria M Richon, Wm Kevin Kelly, et al.
Journal of Geriatric Oncology|May 4, 2024
The rates of septicemia in older adults with prostate cancer treated with abiraterone or enzalutamide: A population-based studyNikita Nikita, Krupa Gandhi, Scott W Keith, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|January 15, 2010
Prostate cancer, comorbidity, and participation in randomized controlled trials of therapyHerta H Chao, Tina Mayer, John Concato, et al.
Cancer Biology & Therapy|May 27, 2024
T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancerJulia Palecki, Amman Bhasin, Andrew Bernstein, et al.
Urologic Oncology|June 21, 2021
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?Jean Hoffman-Censits, Kara Lombardo, David McConkey, et al.
Cancers|September 13, 2025
The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical TrialsAmy L Shaver, Nikita Nikita, Swapnil Sharma, et al.
The Canadian Journal of Urology|October 25, 2011
Screening for prostate cancer: the current evidence and guidelines controversyLeonard G Gomella, Xiaolong S Liu, Edouard J Trabulsi, et al.
Contemporary Clinical Trials|December 25, 2022
Predictors of consenting to participate in a clinical trial among urban cancer patientsRussell K McIntire, Scott W Keith, Thomas Nowlan, et al.
Pageof 4